Current Report Filing (8-k)
13 January 2018 - 8:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 8, 2018
CymaBay Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36500
|
|
94-3103561
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
7999 Gateway Blvd., Suite 130
Newark, CA 94560
(Address
of principal executive offices)
(510)
293-8800
(Registrants telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
On January 8, 2018, CymaBay Therapeutics, Inc. (CymaBay)
announced the receipt of a $5 million milestone payment from Kowa Pharmaceuticals America (Kowa) for the initiation of a study by Kowa evaluating the pharmacokinetics (PK) of arhalofenate in subjects with renal impairment. The
milestone payment was made in connection with CymaBays license agreement with Kowa for the development and commercialization of arhalofenate in the U.S.
CymaBay is also filing this Form
8-K
to refile its PPAR-
d
License Agreement, dated June 30, 2006, by and between CymaBay Therapeutics, Inc. (formerly Metabolex, Inc.) and Janssen Pharmaceutical NV, originally filed with the SEC on November 14, 2014, as Exhibit 10.1 to CymaBays Form
10-Q.
CymaBay is refiling the PPAR-
d
License Agreement to include certain information that was previously redacted as confidential information, but has since been
disclosed publicly.
Item 9.01
|
Financial Statements and Exhibits.
|
*
|
Confidential treatment has been requested for portions of this exhibit.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
CymaBay Therapeutics, Inc.
|
|
|
By:
|
|
/s/ Paul Quinlan
|
Name:
|
|
Paul Quinlan
|
Title:
|
|
General Counsel
|
Dated: January 12, 2018
Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart
From Apr 2024 to May 2024
Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart
From May 2023 to May 2024